- Display 45 Products per page
Published: October 1, 2007 | Price: $6,995.00 – $13,990.00
Complete offer of Vol. I - III Wound Care series. This includes the three volumes in one PDF file. Vol. I: Skin Ulcers Vol. II: Burns Vol. III: Surgical and Trauma WoundsPublished: October 1, 2007 | Price: $995.00 – $1,990.00
For food ingredient companies willing to enter the non-food market, there is over a billion dollars of market potential awaiting them. In addition to increasing the profitability of their traditional product lines, producers of ingredients can potentially expand their markets by moving their products or byproducts into the healthcare sector, where drug producers or manufacturers of some biomedical devices could incorporate them into their products. Kalorama Information's Healthcare Opportunities for Food Ingredient Manufacturers details the sources of ancillary revenue that...Published: October 1, 2007 | Price: $995.00 – $5,990.00
Retail clinics, also known as convenience clinics, represent a disruptive innovation into the U.S. health care market, which evolved from and is uniquely positioned to benefit from the health care system’s shortcomings. These clinics present a new opportunity for retail outlets to earn more revenue from rents and 'indirect' revenues from sales to the retail store as a result of a clinic visit. But there is also an opportunity for diagnostic and pharmaceutical companies to capitalize on this trend. Kalorama...Published: October 1, 2007 | Price: $995.00 – $5,000.00
In five years, Kalorama Information believes that given the role of pharmacists currently and the demands of the US healthcare system, pharmacists will be prescribing in at least six states in five years, creating a trend that will spread to many other states in following years. The state of Florida allows some independing prescribing off an approved list, and many states allow prescription choice from a physicians diagnosis. The cost of copays and the time spent on doctor visits will...Published: November 1, 2007 | Price: $1,995.00 – $6,990.00
Contract Manufacturers are finding opportunities with managers located at OEM corporate headquarters or main manufacturing/assembly operations as they take a hard look at costs and seek outsourcing for cost efficiency. Once satisfied with outsourcing only a small part of operations, OEM companies are now looking to CMs for finished products and finished computer systems. The highly skilled firms who compete in this area meet the challenges of overburdened OEM device companies demanding a ready-to-launch product. Kalorama's OEM Contract Manufacturing in...Published: November 1, 2007 | Price: $1,995.00 – $3,990.00
No longer is cell-based diagnostics simply a histological study of biopsied and surgical tissues. Combinations of tests and technologies are coming together to create a new map of cell diagnostics. Image cytometry, microfluidics, microarrays, and biosensors, special immunohistochemical and in situ hybridization probes are creating new approaches to cell and tissue observation, diagnostics and pharmacogenomics. This report covers assay systems that use cells as the basic source material. Sources of the cells to be studied include peripheral blood, cord blood,...Published: November 1, 2007 | Price: $995.00 – $5,495.00
Analytical microchips can be considered one of the fastest growing technology segments in life sciences. The range of applications to which these miniature laboratories may be directed is very broad — covering fields as different as pharmaceutical development, food testing, clinical diagnostics, forensics, and environmental analysis. Kalorama's Analytical Chip Technology: U.S. Markets for Lab on a Chip, DNA/Gene, Protein and other Microarrasys) 3rd. Edition looks at the market for analytical microchips with a unique methodology -- the market is expressed...Published: November 1, 2007 | Price: $1,500.00 – $7,000.00
Offshoring of clinical trials is increasing as companies in the U.S. are finding challenges in clinical trial research ranging from cost, patient recruitment, patient compliance during participation, qualified professionals, new clinical trial patients, and other problems. This provides an opportunity for BRIC countries and other developing regions to grab a piece of the clinical trial market. Countries such as India and China have a vast population who are interested in taking part in clinical trial research, and these regions can...Published: November 1, 2007 | Price: $3,250.00 – $6,500.00
While insurance is the most common form of payment for healthcare services, increasingly customers are paying for their own expenses. Pharmaceutical, device and diagnostic companies, should recognize that a part of their revenues are originating directly or indirectly from out of pocket expenditures. Health care costs are high and accelerating as a result of a confluence of factors within the broader economy, as well as the health care marketplace. Unique financial services have been created to facilitate non-insurance-paid health care...Published: November 1, 2007 | Price: $3,800.00 – $13,990.00
The trend of medical device outsourcing, or contract manufacturing is increasing. This Kalorama Information report takes an exhaustive look at the total market of OEMs outsourcing device manufacture to CMs. This publication represents the total OEM contract manufacturing market - it is the combination of three volumes in Kalorama Information's OEM Contract Manufacturing in Medical Devices Series. (The publication is combined for PDF delivery and hard copy delivery would come in three seperate volumes) For electronic delivery, a special overview...Published: December 1, 2007 | Price: $995.00 – $7,990.00
Kalorama's 2nd edition of The World Cardiovascular Drugs Market, in its 2nd edition, will steer marketers through the sheer size and diversity of the current market and the potential of new products that will make this therapeutic category among the most competitive of prescription drug segments. Analyst Mary Ann Crandall considers both the exisiting products and the pipeline in this comprehensive market study. The following market segments are covered: Cardiac Glycosides and Positive Inotropic Agents Antihypertensive Agents (ACE Inhibitors, Angiotensin...Published: January 1, 2008 | Price: $995.00 – $7,000.00
Rheumatoid arthritis and lupus belong to a number of autoimmune diseases affecting the musculoskeletal system, multisystemic tissue, and connective tissues. Although a range of autoimmune conditions carry a low prevalence, combined these diseases amount to a growing medical and economic burden. Additionally, autoimmune diseases are accounting for a growing cause of disability in the United States, Europe and worldwide. Kalorama's Worldwide Market for Rheumatoid Arthritis and Lupus Treatments (Autoimmune Disease Markets) is the most comprehensive look at the markets for...Published: January 1, 2008 | Price: $995.00 – $7,990.00
Although much of medicine is focused on the increased aging of the population, children still represent the bulk the dependent population worldwide. Important regulatory factors are at work in the pediatric pharmaceutical market. The recognition of the rights of children to have access to safe and effective drugs and the needs of healthcare providers to have access to age-appropriate drug information continues to have a major effect on all areas of pediatric pharmaceuticals including pediatric biomedical research. Pediatric Drugs, the...Published: January 1, 2008 | Price: $995.00 – $1,990.00
Improved surgical techniques and organ preservation, understanding of immunologic barriers, and the development of newer and more potent immunosuppressives have combined to improve survival of transplant patients and grafts. Rejection remains the major barrier to long-term graft survival in patients, organ transplantation therapy is highly dependent on the success of immunosuppressants to suppress the recipient’s immune responses to the foreign organ. Most transplant patients require lifelong immunosuppressive therapy to prevent rejection, except when human leukocyte antigen (HLA)-identical transplants are used....Published: January 1, 2008 | Price: $4,200.00 – $7,800.00
One of Kalorama's best-selling market research reports, this report provides the reader with a complete analysis of the domestic and international markets for pharmaceuticals to treat skin diseases and disorders. This edition of Worldwide Market for Prescription Dermatological Drugs is the sixth time Kalorama Information has comprehensively studied the dermatology markets. Kalorama has completely re-evaluated the market from the ground up, and in addition to the usual primary research (interviews) of industry participants, clinicians, and regulators, we also conducted scores...Published: January 1, 2008 | Price: $995.00 – $7,990.00
Parts of the gene expression analysis market continue to develop in a somewhat predictable manner, whereas other segments are becoming increasingly complex and volatile. The main products—microarrays and RT-PCR—continue to gain widespread acceptance and to see revenues grow rapidly. However, different products and applications are increasingly being introduced, making the market more fragmented as well as unpredictable. In terms of application, too, the landscape is shifting. Although life-science research is still the dominant application, the clinical diagnostics and prognostics market...Published: February 1, 2008 | Price: $895.00 – $6,990.00
Congestive heart failure is an increasingly important cause of cardiovascular morbidity and mortality. It is the number one cause of hospitalization among individuals aged 65 and over. The United States Medicare system pays out more for the care of congestive heart failure than it does for all forms of cancer combined. While this is a challenge for the US healthcare system, it indicates a strong market opportunity for pharmaceutical companies involved in CHF treatment. Kalorama Information's Congestive Heart Failure, Major...Published: February 1, 2008 | Price: $995.00 – $7,990.00
Pharmaceutical excipients are substances, other than the pharmacologically active drug or prodrug, which are included in the manufacturing process or are contained in the finished pharmaceutical product dosage form. Excipients provide enhanced functionality to the pharmaceuticals, aid the innovations in the drug development and help improve patent life as well. Excipients make the products more functional at a lower cost, a benefit much desired by the pharmaceutical industry that is inundated with pressures to reduce costs. All in all, excipients...Published: February 1, 2008 | Price: $995.00 – $1,990.00
Congestive heart failure, a condition caused by a malfunctioning heart that is unable to pump enough blood and oxygen to meet the body’s needs, is an increasingly important cause of cardiovascular morbidity and mortality. With improvements in the care of other cardiac conditions, more patients have developed dilated cardiomyopathy, which is the final common pathway for many cardiac illnesses and a common cause of congestive heart failure. Kalorama Information's Congestive Heart Failure, Major World Markets series looks at markets for...Published: March 1, 2008 | Price: $995.00 – $7,590.00
Who are the major players in testing for the number two killer in the world? What revenues can companies competing in this market expect in the next five years? How will the impact of trends such as an increased role of pharmacodiagnostics, the use of multiplex assays and a new emphasis on service products influence cancer diagnostics? These questions and more are answered in Kalorama Information's Worldwide Market for Cancer Diagnostics, 3rd Edition. This report contains detailed market data on...Published: March 1, 2008 | Price: $995.00 – $7,800.00
With their ability to differentiate and become an ongoing source of cells that make up critical tissues and organs, stem cells have potential for new regenerative therapies and as new research tools for drug developers to test emerging therapies on diseased cells. For market-watchers in the pharmaceutical industry, the question is what potential they have and where they could take the market. Kalorama Information has tackled that question in Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug...Published: March 1, 2008 | Price: $995.00 – $3,990.00
Pharmaceutical manufacturers are utilizing new RIFD technologies to deal with multiple challenges they face in the manufacturing process. This Kalorama Information report discussions the solutions available, and covers the opportunities available to technology companies to provide services to this sector. Full coverage of the market for RFID technologies in pharmaceutical manufacturing operations is provided, including. Explanation of RFID Technologies Cost Savings from Implementation Total Market for RFID Technologies in Pharma Manufacturing Market Forecasts Major Companies Involved in RFID and...Published: March 15, 2008 | Price: $6,995.00 – $13,990.00
Pharmaceutical marketers will face a challenging time in 2008 by all reports. Understanding the dynamics of the market can assist in better planning and strategy. This Kalorama Information Report Bundle combines 5 of the most important topics for those in the pharmaceutical industry in a strategic planning, business development or marketing. Grouped together, this report reprsents over 60% off the individual report price. Retail Clinics These entities may change how America gets healthcare, and may become important outlets for pharmaceutical...Published: April 1, 2008 | Price: $995.00 – $7,000.00
In one sense, the opportunity for follow-on proteins is as good as ever. Some of the biggest-selling biologics developed during the first phase of the biotechnology revolution in the 1980s, including human growth hormone (hGH) and insulin, have lost patent protection or are set to lose patent protection in the US in 2007 and beyond. But there are also regulatory challenges to marketing follow-on biologics in the U.S. that companies will need to navigate to prosper. In this report, Biogenerics:...Published: April 1, 2008 | Price: $995.00 – $7,990.00
Generics, so long the force that has shaken up the branded pharmaceutical industry, is now facing its own challenges as an industry. While growth indications are strong, there are challenges for generic companies. In the next two years, consolidation will most likely rise; the sector is expected to be rocked by increased competition from companies in Eastern Europe, India and China, as well as brand name companies seeking to protect their franchises by moving into generics. Kalorama Information's World Market...Published: April 1, 2008 | Price: $995.00 – $8,200.00
Few areas of pharmaceuticals have seen the fast-moving developments in the marketplace that the vaccine market has in 2007 and 2008. Since Kalorama Information last updated Kalorama Information's The World Market for Vaccines in the first quarter of last year, new products and better than expected profits have transformed the vaccine marketplace. Approvals that have been granted for products such as RotaTeq, Pentacel, Adacel and Zostavax and FluMist are now impacting the market. The launch and execution of the first...Published: April 1, 2008 | Price: $500.00 – $3,990.00
Lagging FDA approvals led to a brief absence of Rx to OTC switches in the pharmaceutical marketplace, but 2006 and 2007 saw a number of switches, and Kalorama Information believes this product management tactic will continue to be aggressively utilized as companies seek ways to extend revenue life. Kalorama Information's The Return of the Rx to OTC Switch: Market Analysis and Product Management Strategies contians a complete overview of the US market for prescription drugs likely to switch in the...Published: May 1, 2008 | Price: $3,500.00 – $7,990.00
2008 has seen no letdown in the use of wireless technologies in healthcare. The clinical environment is a highly mobile one, and physicians, nurses and other clinical operators have a real need for fast information they can act upon. Wireless technologies fit healthcare well. It's therefore no surprise that hospitals are dedicating large portions of current and future budgets to IT development and wireless is likely to be among their choices. Kalorama’s Wireless in Healthcare 2008 is your guide to...Published: May 1, 2008 | Price: $995.00 – $6,400.00
Over-the-counter (OTC) drugs are well situated to capitalize on worldwide economic conditions. Customers in the US and in the world under time constraints and tight budgets prefer OTC and are opting to self-medicate where possible. Developing and petro-rich nations are pushing world demand for pharmaceuticals. Pharmacists are favoring OTCs, and are a driving force behind a new class of 'behind the counter' (BTC) drugs. The aging of the population and an increase in medical conditions generally continues to bode well...Published: May 1, 2008 | Price: $995.00 – $5,600.00
2008 has seen no decrease in attention on wound care products. The aging of the population and a constant demand for products that speed healing and improve outcomes drives the wound care industry. For market watchers, this makes for a dynamic market that has changed in recent years with biological developments. Kalorama Information's analyst Mary Ann Crandall has reviewed the Wound Care Industry in several editions of wound care market reports and has participated in industry panels. Kalorama Information's three-volume...Published: May 1, 2008 | Price: $995.00 – $1,990.00
Since the arrival of drug-eluting (called drug-eluding by some) technology a few years ago with the promise of reducing restenosis, questions abound surrounding the future of the stent market: After numerous clinical studies and mixed cost-effectiveness results, how is drug-eluding technology expected to peform in the future? What can companies do to best market this technology in the healthcare system of the US and 6 other major world markets? What are the market trends to watch that will determine growth...Published: May 1, 2008 | Price: $3,500.00 – $7,000.00
2008 has seen no decrease in the opportunities available for outsourcing drug discovery, for a number of reasons. New technologies increase the number of targets and accelerate the identification of active compounds. There is increasing pressure to develop new lead compounds due to the near-term loss of patent protection for many drug product. And there is also pressure to reduce the time spent in drug discovery and to bring drugs to market sooner, as well as the ever-present cost considerations....Published: June 1, 2008 | Price: $1,995.00 – $7,990.00
SNPs (single nucleotide polymorphisms), single base pair mutations that occur at a specific site in the DNA sequence, are the most common type of genetic variation between human beings. Because they are responsible for over 80% of the variation between two individuals, SNPs are ideal for the task of hunting for correlations between genotype and behavior or quality exhibited by a living organism. The use of SNP analysis has spread into numerous areas in recent years. But diagnostics and pharmacogenomics...Published: June 1, 2008 | Price: $2,995.00 – $5,990.00
This Kalorama Information report, Companion Diagnostics Markets (A Realistic Assessment of the Opportunities, Challenges, Key Players and Important Trends in Personalized Medicine) is truly a real-world guide to the potential market for companion diagnostics. Essentially the co-development of testing products to enhance the value and efficacy of a therapeutic, companion diagnostics is widely seen as an important growth strategy in both the diagnostic and pharmaceutical industries. It is envisioned as a pathway to personalized medicine, where the right therapeutic is...Published: July 1, 2008 | Price: $500.00 – $7,000.00
Pharmaceutical markets in Brazil, Russia, India and China rank among the top twenty markets in the world with the potential to move up in ranking rather quickly. (China’s pharmaceutical market, for instance, is expected to show double-digit growth over the next five years.) Developing regions and petro-rich nations will be an integral part of expansion for companies looking to capture a larger portion of the worldwide market. Kalorama's Pharmaceutical Markets in Brazil, Russia, India and China (BRIC nations) takes a...Published: July 1, 2008 | Price: $3,995.00 – $7,990.00
As Kalorama publishes its second edition of this detailed report on the long term care industry and all of its segments, there is no decrease in demand or activity for everything from nursing homes, to home care, to hospices. The U.S. long care industry has experienced strong growth from 2002 through 2007 and this growth is expected to accelerate through the forecast period as the U.S. population continues to age and demand rises for long term care. Ongoing cost containment...Published: August 1, 2008 | Price: $3,500.00 – $7,000.00
The aging of the population, namely the baby boomer demographic segment is driving the market for facial rejuvenation products. The size and wealth of this aging segment and its overwhelming desire to retain a youthful appearance are driving growth for aesthetic procedures. Worldwide, billions of dollars are spent annually on facial rejuvenation products and services. This report, Facial Rejuvenation Markets Worldwide from Kalorama Information, covers both products and services in this market. For this report, products pertain to: Topical Rejuvenation...Published: August 1, 2008 | Price: $1,500.00 – $4,995.00
Alzheimer’s Disease is the most common cause of dementia, constituting 60% to 70% of all cases, and the risk with the disease doubles every 5 years after age 65. Incidence of the disease is increasing, and the resulting attention given to Alzheimer's Disease has encouraged development of new treatments. There is an opportunity for pharmaceutical companies to compete in this market, as Kalorama analyst Melissa Elder outlines in this study. This report includes incidence of Alzheimer’s disease worldwide with information...Published: August 1, 2008 | Price: $1,500.00 – $7,000.00
The benefits of automation in the clinical laboratory are well documented. They involve replacing manual, potentially dangerous, error-prone steps with automated processes requiring minimal operator intervention. This approach can increase productivity, decrease turnaround time, improve staff safety, minimize errors, improve the handling of specimens, and allow labs to reallocate personnel to more important and productive tasks. For drug discovery, automation also offers benefits. bringing a new drug to market has been both a very time-intensive, laborious and expensive undertaking. This...Published: August 1, 2008 | Price: $2,995.00 – $5,990.00
The market for respiratory disposables and reusable accessories is witnessing dynamic changes. The market factors influencing demand in the U.S. are also present in Europe and the Asia/Pacific region — the aging of the population, technological trends and society’s acceptance of people with disabilities. Kalorama's World Market for Respiratory Equipment and Disposables represents the third time that Kalorama Information has tackled this important device market. This report analyzes the worldwide market for respiratory disposables and reusables, including the following segments:...Published: August 1, 2008 | Price: $1,500.00 – $7,000.00
Test services, once the norm in the diagnostics industry, then abandoned for reagent sales, are now making a comeback. IVD companies have established cGMP and CLIA-registered labs by which they offer their proprietary tests to physicians, hospitals and reference labs. These tests are outside the oversight of the traditional FDA and CE Mark test commercialization avenue in the U.S, and Europe and so are thought to come to market by what may seem to be the back door. Kalorama has...Published: August 1, 2008 | Price: $2,995.00 – $5,000.00
A perfect supplemental information resource for customers who have already purchased The Worldwide Market for In Vitro Diagnostic Tests, 6th Edition, The IVD Market Research Supplement bundle studies and quantifies in greater detail some of the important areas that will have a transforming impact on the diagnostic industry: • Companies are now performing diagnostic tests as a service rather than simply selling kit to laboratories. Are companies seeking profit, or a 'back-door' around FDA regulations? And does it have growth...Published: September 1, 2008 | Price: $3,500.00 – $7,000.00
Minimally invasive surgery (MIS) allows doctors to perform many complicated operations with a short hospital stay. It is a safe, feasible, and patient-friendly method of performing an operation. The report includes product information, procedure volume data, world demographics; and other general issues affecting the MIS device market. Information is presented as a worldwide overview, with a focus on the US. A market summary includes market analysis by intended use and a competitive analysis of leading providers. Additionally key company profiles...Published: September 1, 2008 | Price: $1,500.00 – $6,995.00
Infusion pumps are used to infuse necessary fluids, which includes medications and/or nutrients, to a patient’s circulatory system. Infusion pumps are often used in situations where continuous monitoring and treatment by a nurse or other health staff would be expensive, impractical, or unreliable. For the purpose of this study, we have classified two general types of infusion pumps: General Purpose Infusion Pumps Specialty Infusion Pumps General purpose infusion pumps are used in a variety of applications and settings from basic...Published: September 1, 2008 | Price: $2,250.00 – $5,500.00
Contract Manufacturers seeking to partner with global marketers can find the best opportunities making the medical devices that drive the best sales and growth for global marketers. This report covers contract manufacturing (CM) in several medical devices that show promising growth for the next five years. The report details the following areas and provides forecasts for the next five years: Cardiac Pace Makers Implantable Defibrillators Catheters Syringes Orthopedic Hip Implants Orthopedic Knee Implants Oxygen Concentrators (Standard and Portable) Continuous...